Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27402984 | 0.82 | ALDH1A1 (0.36) | DGAT1CA12CA1CA7CA14 | |
| SCHEMBL14450896 | 0.77 | DGAT1 (0.35) | DGAT1CA12CA14 | |
| SCHEMBL27621695 | 0.77 | GAA (0.36) | DGAT1CA12CA1CA7CA14 | |
| SCHEMBL27821298 | 0.77 | CA12 (0.33) | DGAT1CA12CA1CA7CA14 | |
| SCHEMBL23306962 | 0.76 | STING1 (0.35) | DGAT1 | |
| SCHEMBL27833199 | 0.76 | CTSK (0.31) | DGAT1 | |
| SCHEMBL27907193 | 0.76 | CYP2D6 (0.32) | CA1CA7 | |
| SCHEMBL1088039 | 0.75 | CA1 (0.37) | DGAT1CA12CA1CA7CA14 | |
| SCHEMBL27472718 | 0.74 | CYP2D6 (0.37) | CA1CA7 | |
| SCHEMBL27404694 | 0.74 | CYP2D6 (0.37) | CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4104865-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3468996-B1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-3835322-A2 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| EP-3735990-A1 | ANTIBODY DRUG CONJUGATES WITH CELL PERMEABLE BCL-XL INHIBITORS | Abbvie Inc. (US) | 2020-11-11 | — | — | EP | disclosed |
| EP-3229844-B1 | ANTIBODY DRUG CONJUGATES WITH CELL PERMEABLE BCL-XL INHIBITORS | ABBVIE INC (US) | 2020-03-04 | — | — | EP | disclosed |
| WO-2017214456-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017214462-A2 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017214282-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017214335-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |